Wellington Management Group LLP Raises Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Wellington Management Group LLP increased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 14.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,307,326 shares of the company’s stock after purchasing an additional 688,967 shares during the quarter. Wellington Management Group LLP owned approximately 0.08% of Kymera Therapeutics worth $213,514,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in KYMR. Blue Trust Inc. grew its holdings in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after buying an additional 270 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in Kymera Therapeutics by 1.7% in the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock worth $1,649,000 after acquiring an additional 684 shares during the period. KBC Group NV raised its holdings in Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Kymera Therapeutics by 8.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock worth $534,000 after purchasing an additional 915 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Kymera Therapeutics by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company’s stock worth $552,000 after purchasing an additional 1,311 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KYMR. BTIG Research began coverage on Kymera Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $60.00 target price on the stock. BMO Capital Markets started coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective on the stock. HC Wainwright raised their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Friday, December 27th. Finally, Stephens reiterated an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $56.36.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $26.36 on Thursday. The firm has a market capitalization of $1.71 billion, a PE ratio of -11.26 and a beta of 2.22. Kymera Therapeutics, Inc. has a one year low of $24.36 and a one year high of $53.27. The stock’s 50 day moving average price is $34.88 and its 200 day moving average price is $41.37.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. On average, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ellen Chiniara sold 3,129 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This represents a 5.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,788 shares of company stock worth $455,202 over the last ninety days. Corporate insiders own 15.82% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.